Israel Englander Cerevel Therapeutics Holdings, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $20.7 Million - $22.7 Million	531,972 Added 36.12%	2,004,795 $82 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $14.8 Million - $15.7 Million	361,711 Added 32.55%	1,472,823 $62.3 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $18.9 Million - $39.5 Million	931,317 Added 517.99%	1,111,112 $47.1 Million
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $6.82 Million - $10.1 Million	-285,195 Reduced 61.33%	179,795 $5.72 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $10.6 Million - $16.4 Million	464,990 New	464,990 $11.3 Million

147

127M

1.91M

2.7M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.